MTOR and cancer: Supporting our findings, mRNA levels of NOP56 significantly correlate with that of mTOR pathway genes in KRAS-mutant cancer cells and lung adenocarcinomas, and NOP56 expression is a predictive marker of sensitivity to mTOR inhibitors in KRAS-mutant but not KRAS-wild-type cancer cells.